234 related articles for article (PubMed ID: 18703706)
21. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Vu K; Busaidy N; Cabanillas ME; Konopleva M; Faderl S; Thomas DA; O'Brien S; Broglio K; Ensor J; Escalante C; Andreeff M; Kantarjian H; Lavis V; Yeung SC
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):355-62. PubMed ID: 22658895
[TBL] [Abstract][Full Text] [Related]
22. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Chevallier P; Pigneux A; Robillard N; Ayari S; Guillaume T; Delaunay J; Eveillard M; Dumas PY; Lippert E; Mohty M; Leguay T
Leuk Res; 2012 Mar; 36(3):311-5. PubMed ID: 22172463
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
[TBL] [Abstract][Full Text] [Related]
26. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
27. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Dworzak MN; Schumich A; Printz D; Pötschger U; Husak Z; Attarbaschi A; Basso G; Gaipa G; Ratei R; Mann G; Gadner H
Blood; 2008 Nov; 112(10):3982-8. PubMed ID: 18780832
[TBL] [Abstract][Full Text] [Related]
28. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
[TBL] [Abstract][Full Text] [Related]
29. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
30. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
[No Abstract] [Full Text] [Related]
31. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
32. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Maury S; Chevret S; Thomas X; Heim D; Leguay T; Huguet F; Chevallier P; Hunault M; Boissel N; Escoffre-Barbe M; Hess U; Vey N; Pignon JM; Braun T; Marolleau JP; Cahn JY; Chalandon Y; Lhéritier V; Beldjord K; Béné MC; Ifrah N; Dombret H;
N Engl J Med; 2016 Sep; 375(11):1044-53. PubMed ID: 27626518
[TBL] [Abstract][Full Text] [Related]
34. The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Garcia-Manero G; Kantarjian HM
Hematol Oncol Clin North Am; 2000 Dec; 14(6):1381-96, x-xi. PubMed ID: 11147229
[TBL] [Abstract][Full Text] [Related]
35. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
[No Abstract] [Full Text] [Related]
37. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
[TBL] [Abstract][Full Text] [Related]
38. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
39. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.
Mannelli F; Gianfaldoni G; Intermesoli T; Cattaneo C; Borlenghi E; Cortelazzo S; Cavattoni I; Pogliani EM; Fumagalli M; Angelucci E; Romani C; Ciceri F; Corti C; Scattolin A; Cortelezzi A; Mattei D; Audisio E; Spinelli O; Oldani E; Bosi A; Rambaldi A; Bassan R
Haematologica; 2012 Apr; 97(4):568-71. PubMed ID: 22058217
[TBL] [Abstract][Full Text] [Related]
40. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
